Aimmune Therapeutics Inc. (NASDAQ:AIMT) is Attracting Smart Money

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Aimmune Therapeutics Inc. (NASDAQ:AIMT) reported that Longitude Capital Partners Ii, Llc. has picked up 6,013,134 of common stock as of 2017-02-21.

The acquisition brings the aggregate amount owned by Longitude Capital Partners Ii, Llc. to a total of 6,013,134 representing a 14.2% stake in the company.

For those not familiar with the company, Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation. For patients in the up-dosing phase of the AR101 treatment regimen, AR101 would be provided in a series of color coded pharmaceutical grade capsules of various dose levels.

A glance at Aimmune Therapeutics Inc. (NASDAQ:AIMT)’s key stats reveals a current market capitalization of 1.00 billion based on 50.04 million shares outstanding and a price at last close of $20.07 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-03-19, Enright picked up 45,440 at a purchase price of $14.15. This brings their total holding to 7,513,134 as of the date of the filing.

On the sell side, the most recent transaction saw Barrowcliffe unload 20,000 shares at a sale price of $25.00. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Aimmune Therapeutics Inc. (NASDAQ:AIMT) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.



Skip to content